Search — EtoBox

1 work shown

Showing the first matches. Checking the full catalogue…

Books

Homecoming Queen (carter House Girls, Book 3)

Melody Carlson

pdfen2009

Read now

Research articles

S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial

Takazoe · Gastroenterology

2009PDF100 KB

Oral Treatment with a Novel Small Molecule Alpha 4 Integrin Antagonist, AJM300, Prevents the Development of Experimental Colitis in Mice

Sugiura · Journal of Crohn s and Colitis

2013PDF664 KB

Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients with Active Ulcerative Colitis

Yoshimura · Gastroenterology

2015PDF1.5 MB

370 AJM300, an Oral A4 Integrin Antagonist, for Active Ulcerative Colitis: a Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Study

Watanabe · Gastrointestinal Endoscopy

2014PDF69 KB

370 AJM300, an Oral α4 Integrin Antagonist, for Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2A Study

Watanabe · Gastroenterology

2014PDF126 KB

AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: a randomised controlled trial in healthy male subjects

Fukase · British Journal of Clinical Pharmacology

2019PDF1.6 MB

AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects

Fukase · British Journal of Clinical Pharmacology

2020PDF1.6 MB

M1647 An Orally Active Alpha4 Integrin Antagonist AJM300 Prevents the Development of Experimental Colitis Induced By Adoptive Transfer of IL-10 Deficient CD4+ T Cells in Mice

Sugiura · Gastroenterology

2009PDF49 KB

A Novel, Orally Active Alpha 4 Integrin Antagonist, AJM300 Prevents the Development of Experimental Colitis Induced by Adoptive Transfer of IL-10 Deficient CD4+ T Cells in Mice.

Sugiura · American Society for Pharmacology & Experimental Therapeutics (ASPET)

2012PDF46 KB

An Orally Available Alpha 4 (α4) Integrin Antagonist AJM300 Increases the Peripheral Lymphocyte Counts: The Relationship Between Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy Against Colitis Model in Mice

Sugiura · Gastroenterology

2011PDF41 KB

Genres

Books

Homecoming Queen (carter House Girls, Book 3)

Research articles

S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial

Oral Treatment with a Novel Small Molecule Alpha 4 Integrin Antagonist, AJM300, Prevents the Development of Experimental Colitis in Mice

Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients with Active Ulcerative Colitis

370 AJM300, an Oral A4 Integrin Antagonist, for Active Ulcerative Colitis: a Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Study

370 AJM300, an Oral α4 Integrin Antagonist, for Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2A Study

AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: a randomised controlled trial in healthy male subjects

AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects

M1647 An Orally Active Alpha4 Integrin Antagonist AJM300 Prevents the Development of Experimental Colitis Induced By Adoptive Transfer of IL-10 Deficient CD4+ T Cells in Mice

A Novel, Orally Active Alpha 4 Integrin Antagonist, AJM300 Prevents the Development of Experimental Colitis Induced by Adoptive Transfer of IL-10 Deficient CD4+ T Cells in Mice.

An Orally Available Alpha 4 (α4) Integrin Antagonist AJM300 Increases the Peripheral Lymphocyte Counts: The Relationship Between Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy Against Colitis Model in Mice

Genres

Genres

Books

Homecoming Queen (carter House Girls, Book 3)

Research articles

S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial

Oral Treatment with a Novel Small Molecule Alpha 4 Integrin Antagonist, AJM300, Prevents the Development of Experimental Colitis in Mice

Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients with Active Ulcerative Colitis

370 AJM300, an Oral A4 Integrin Antagonist, for Active Ulcerative Colitis: a Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Study

370 AJM300, an Oral α4 Integrin Antagonist, for Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2A Study

AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: a randomised controlled trial in healthy male subjects

AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects

M1647 An Orally Active Alpha4 Integrin Antagonist AJM300 Prevents the Development of Experimental Colitis Induced By Adoptive Transfer of IL-10 Deficient CD4+ T Cells in Mice

A Novel, Orally Active Alpha 4 Integrin Antagonist, AJM300 Prevents the Development of Experimental Colitis Induced by Adoptive Transfer of IL-10 Deficient CD4+ T Cells in Mice.

An Orally Available Alpha 4 (α4) Integrin Antagonist AJM300 Increases the Peripheral Lymphocyte Counts: The Relationship Between Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy Against Colitis Model in Mice